Weighted Average Number of Shares Outstanding, Diluted of Vistagen Therapeutics, Inc. from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Vistagen Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • Vistagen Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Dec 2025 was 42,234,405, a 38% increase year-over-year.
  • Vistagen Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 30,877,029, a 60% increase from 2023.
  • Vistagen Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 19,354,500, a 178% increase from 2022.
  • Vistagen Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 6,958,749.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Vistagen Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 42,234,405 +11,522,533 +38% 01 Oct 2025 31 Dec 2025 10-Q 12 Feb 2026 2026 Q3
Q3 2025 35,749,160 +5,116,813 +17% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2026 Q2
Q2 2025 31,930,665 +1,327,230 +4.3% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2026 Q1
Q1 2025 30,877,029 +11,522,529 +60% 01 Jan 2025 31 Mar 2025 10-K 17 Jun 2025 2025 FY
Q4 2024 30,711,872 +1,323,787 +4.5% 01 Oct 2024 31 Dec 2024 10-Q 12 Feb 2026 2026 Q3
Q3 2024 30,632,347 +20,589,817 +205% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2026 Q2
Q2 2024 30,603,435 +23,266,430 +317% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2026 Q1
Q1 2024 19,354,500 01 Jan 2024 31 Mar 2024 10-K 17 Jun 2025 2025 FY
Q4 2023 29,388,085 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2025 Q3
Q3 2023 10,042,530 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2025 Q2
Q2 2023 7,337,005 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2025 Q1
Q4 2015 1,765,641 +463,325 +36% 01 Oct 2015 31 Dec 2015 10-Q 16 Feb 2016 2016 Q3
Q3 2015 1,624,371 +325,256 +25% 01 Jul 2015 30 Sep 2015 10-Q 16 Nov 2015 2016 Q2
Q1 2015 1,466,402 +303,766 +26% 01 Jan 2015 31 Mar 2015 10-K 24 Jun 2016 2016 FY
Q4 2014 1,302,316 +191,787 +17% 01 Oct 2014 31 Dec 2014 10-K 24 Jun 2016 2016 FY
Q3 2014 1,299,115 +170,963 +15% 01 Jul 2014 30 Sep 2014 10-K 24 Jun 2016 2016 FY
Q2 2014 1,229,504 +167,960 +16% 01 Apr 2014 30 Jun 2014 10-K 24 Jun 2016 2016 FY
Q1 2014 1,162,636 -19,073,855 -94% 01 Jan 2014 31 Mar 2014 10-K 29 Jun 2015 2015 FY
Q4 2013 1,110,529 -17,181,772 -94% 01 Oct 2013 31 Dec 2013 10-K 29 Jun 2015 2015 FY
Q3 2013 1,128,152 -15,966,681 -93% 01 Jul 2013 30 Sep 2013 10-K 29 Jun 2015 2015 FY
Q2 2013 1,061,544 -15,781,111 -94% 01 Apr 2013 30 Jun 2013 10-K 29 Jun 2015 2015 FY
Q1 2013 20,236,491 +3,693,774 +22% 01 Jan 2013 31 Mar 2013 10-K 18 Jul 2013 2012 FY
Q4 2012 18,292,301 +2,256,440 +14% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014 2013 Q3
Q3 2012 17,094,833 +1,852,929 +12% 01 Jul 2012 30 Sep 2012 10-K 18 Jul 2013 2012 FY
Q2 2012 16,842,655 +5,736,801 +52% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q1
Q1 2012 16,542,717 +11,301,607 +216% 01 Jan 2012 31 Mar 2012 10-K 18 Jul 2013 2012 FY
Q4 2011 16,035,861 +10,795,751 +206% 01 Oct 2011 31 Dec 2011 10-K 18 Jul 2013 2012 FY
Q3 2011 15,241,904 +10,000,794 +191% 01 Jul 2011 30 Sep 2011 10-K 18 Jul 2013 2012 FY
Q2 2011 11,105,854 +5,865,744 +112% 01 Apr 2011 30 Jun 2011 10-K 18 Jul 2013 2012 FY
Q1 2011 5,241,110 01 Jan 2011 31 Mar 2011 10-K 02 Jul 2012 2011 FY
Q4 2010 5,240,110 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012 2011 Q3
Q3 2010 5,241,110 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011 2011 Q2
Q2 2010 5,240,110 01 Apr 2010 30 Jun 2010 10-Q 22 Aug 2011 2011 Q1

Vistagen Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 30,877,029 +11,522,529 +60% 01 Apr 2024 31 Mar 2025 10-K 17 Jun 2025 2025 FY
2023 19,354,500 +12,395,751 +178% 01 Apr 2023 31 Mar 2024 10-K 17 Jun 2025 2025 FY
2022 6,958,749 01 Apr 2022 31 Mar 2023 10-K 11 Jun 2024 2024 FY
2015 1,767,957 +449,144 +34% 01 Apr 2015 31 Mar 2016 10-K 24 Jun 2016 2016 FY
2014 1,318,813 +219,597 +20% 01 Apr 2014 31 Mar 2015 10-K 24 Jun 2016 2016 FY
2013 1,099,216 -19,740,725 -95% 01 Apr 2013 31 Mar 2014 10-K 29 Jun 2015 2015 FY
2012 20,839,941 +6,103,290 +41% 01 Apr 2012 31 Mar 2013 10-Q 12 Aug 2014 2014 Q1
2011 14,736,651 +9,495,541 +181% 01 Apr 2011 31 Mar 2012 10-K 18 Jul 2013 2012 FY
2010 5,241,110 01 Apr 2010 31 Mar 2011 10-K 02 Jul 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.